- FDA approves Watson's generic version of Boniva
- Dr. Reddy's launches generic osteoporosis drug
- FDA approves first effervescent tablet for osteoporosis
- CRN, National Osteoporosis Foundation to host webinar on calcium, vitamin D for pharmacists, clinicians
- CVS Caremark announces expansion of Pharmacy Advisor program
SAN ANTONIO — A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.
Mission Pharmacal announced Tuesday a patent and technology licensing agreement with Freienbach, Switzerland-based EffRx Pharmaceuticals for Binosto (alendronate sodium) effervescent tablets in the United States and Canada. Financial terms were not disclosed.
The Food and Drug Administration approved the drug last month for osteoporosis in men and postmenopausal women. The companies plan to make the drug available later this year. The drug is a strawberry-flavored effervescent tablet designed to rapidly dissolve in water.
"Binosto provides an important new innovation for patients with osteoporosis," National Osteoporosis Foundation president Robert Recker said. "Binosto offers those patients that struggle with taking tablets the opportunity to obtain the proven fracture prevention of alendronate in an easy-to-take, buffered solution."